Ultragenyx Announces Phase 3 Aspire Results for Apazunersen (GTX-102) in Angelman Syndrome
Phase 3negativeapazunersenNegative
AI Analysis
Summary
Ultragenyx announced that its Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome did not meet its primary endpoint. The failed trial is a significant setback for the company's development of this therapeutic candidate.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Phase 3 Aspire study did not achieve primary endpoint
Importance:8/10
Sentiment:
-0.80
Phase 3 failureAngelman syndromeantisense oligonucleotideprimary endpoint miss
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 2, 2026 6:09 AM